Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 12/20 | 0.53 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.52 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.50 |
| ▸ | HTR3B | O95264 | 1/20 | 0.50 |
| ▸ | HTR3A | P46098 | 1/20 | 0.50 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.50 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NOS3 | P29474 | 2/20 | 0.42 |
| ▸ | NOS1 | P29475 | 2/20 | 0.42 |
| ▸ | NOS2 | P35228 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL146909 | 0.81 | IDO1 (0.78) | IDO1LMNAMAPT | |
| SCHEMBL4729200 | 0.79 | IDO1 (0.53) | IDO1 | |
| SCHEMBL4727684 | 0.79 | GAA (0.51) | IDO1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL4728320 | 0.75 | MAPT (0.54) | IDO1TLR7MAPTKDM4E | |
| SCHEMBL4728326 | 0.75 | MAPT (0.54) | IDO1TLR7MAPTKDM4E | |
| SCHEMBL4928790 | 0.73 | IDO1 (0.55) | IDO1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL4725777 | 0.73 | IDO1 (0.47) | IDO1LMNAMAPTKDM4E | |
| Trifluoroacetic Acid SCHEMBL16581962 | 0.70 | IDO1 (0.56) | IDO1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL21372683 | 0.70 | IDO1 (0.46) | IDO1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL14214642 | 0.69 | MAPT (0.56) | IDO1TLR7MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119491-A1 | AMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION (US) | 2008-05-22 | — | — | US | claimed |
| WO-2008036643-A2 | AMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION (US) | 2008-03-27 | — | — | WO | claimed |
| US-20080119491-A1 | AMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION (US) | 2008-05-22 | — | — | US | disclosed |
| US-20080119491-A1 | AMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION (US) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119491-A1 | AMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, INMT | IDO1 1/4885TLR7 2234/4885HTR3E 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.